Key Highlights
- 72.24% was the gain for Sangrix (NASDAQ:SGRX), to USD 1.18 on October 16, 2026 per published market data, on 18.23 million shares and relative volume of 7.15. Turnover of USD 21.5 million is 9.6 times the USD 2.25 million market value, own arithmetic.
- USD 350 million is the private placement tied to the completed Velaris Therapeutics acquisition by Alaunos Therapeutics (NASDAQ:TCRT), per the 8-K dated October 13, 2026. Published market data show a further 20.13% rise to USD 2.62, 82.5% above the USD 1.4357 placement price.
- 16.66% was the gain for Netcapital (NASDAQ:NCPL), to USD 2.31 on 12.13 million shares per published market data, with no company-specific catalyst identified. The SEC alleges USD 14 million of improperly recorded revenue, and a Nasdaq compliance plan is due October 23, 2026.
- 14.81% was the gain for Reliance Global Group (NASDAQ:EZRA), to USD 2.48 on relative volume of 0.29, with no catalyst identified. Its USD 50 million equity line is 12 times the USD 4.17 million market value, own arithmetic on two published figures.
Sangrix (NASDAQ:SGRX)
Sangrix, formerly Bit Origin and listed as BTOG until September 4, 2026, rose after an October 15, 2026 release announcing a November delivery schedule for a 128-GPU Nvidia Blackwell B300 project in Malaysia; the release text was not available for review. The company agreed on June 29, 2026 to buy the servers for USD 11 million, USD 1 million in cash and USD 10 million through pre-funded warrants, and expects fixed monthly rental of USD 368,640, a 29.8-month gross payback, own arithmetic. Income begins only after delivery and deployment, and delays, supplier performance or data center readiness could change the schedule. The warrant covers 1,291,573 Class A shares after the 1-for-5 reverse split of August 21, 2026, equal to 176% of the 733,246 shares outstanding on June 30, own arithmetic, so exercise dilutes holders. Market value is USD 2.25 million on one published figure and USD 1.89 million on another, so turnover is 9.6 to 11.4 times market value, own arithmetic. Sangrix (NASDAQ:SGRX) holds 67,543,745 Dogecoin, worth USD 4.86 million at the June 30 price of USD 0.0720, own arithmetic, and its 20-F warns the shares could be delisted.
Alaunos Therapeutics (NASDAQ:TCRT)
On October 13, 2026, Alaunos completed its acquisition of Velaris Therapeutics, alongside a USD 350 million private placement at USD 1.4357 per common share, with Fairmount-affiliated funds investing USD 100.0 million. The stock rose 67.6% that day and a further 20.13% to USD 2.62 on 13.91 million shares, USD 36.4 million of turnover, own arithmetic. The company estimates cash lasts into 2029. New Series B and Series C preferred shares convert into common stock only after stockholder approval under Nasdaq rules; without approval, holders may require cash settlement six months after issuance. As-converted shares of 358.59 million imply USD 939.5 million of equity value at USD 2.62, own arithmetic, against a published market value of USD 7.67 million that appears to exclude the preferred. A resale registration is due within 30 days of closing. Alaunos Therapeutics (NASDAQ:TCRT) disclosed a Nasdaq stockholders' equity notice on October 5, a reverse split is on the proxy list, and VLR199 data are guided to 2028.
Netcapital (NASDAQ:NCPL)
No filing explains the 16.66% rise. Turnover of USD 28.0 million is 154% of the USD 18.13 million market value, own arithmetic, and the 7.85 million shares implied by that value are fewer than the volume, so the data are inconsistent or the shares turned over more than once. The SEC filed a complaint in August 2026 alleging USD 14 million of improperly recorded consulting revenue and forged offering documents, naming the company and its chief financial officer; these are allegations, not findings. Preliminary fiscal 2026 revenue was USD 460,883, down 47%, against a net loss of USD 9.23 million, 20 times revenue, own arithmetic. The audited Form 10-K for the year ended April 30, 2026 is unfiled. Nasdaq set an October 23, 2026 plan deadline, extendable to February 9, 2027 if accepted, plus a bid-price cure date of February 1, 2027. Netcapital (NASDAQ:NCPL) used a 1-for-70 reverse split in July 2024, and splits distort per-share figures such as EPS. Cash, going concern language, warrants and at-the-market capacity were not disclosed in the filings reviewed.
Reliance Global Group (NASDAQ:EZRA)
Reliance Global Group rose 14.81% on 239,250 shares, which implies average volume of 825,000, own arithmetic. Turnover was USD 593,340, 14.2% of market value, own arithmetic. No company-specific catalyst was identified in the filings and releases reviewed through October 16, 2026. An equity line lets the company sell shares to an investor in tranches at a discount, so each draw can pressure the price. In 2026 it also sold 278,978 shares through an at-the-market program for USD 1.12 million and raised USD 2.53 million in a Series K offering with warrants. A 1-for-40 reverse split took effect on May 18, 2026, Nasdaq confirmed bid compliance on June 3, and another split is restricted for one year. Second quarter commission income fell 31.7% to USD 2.11 million, with a net loss of USD 1.99 million. Unrestricted cash of USD 843,513 covers 1.3 months of that loss, own arithmetic. Reliance Global Group (NASDAQ:EZRA) states there is no substantial doubt regarding going concern, and published EPS of negative USD 19.86 is not reconciled to filings.
Where Things Stand
Trading activity and dated corporate events, not improving earnings, explain these moves. Sangrix (NASDAQ:SGRX) has a defined project but no income yet. Alaunos Therapeutics (NASDAQ:TCRT) is a financing event with heavy dilution potential. Netcapital (NASDAQ:NCPL) carries SEC allegations and no identified catalyst. Reliance Global Group (NASDAQ:EZRA) pairs a USD 50 million equity line with a USD 4.17 million market value. Own arithmetic ranks session gain: Sangrix 72.24%, Alaunos 20.13%, Netcapital 16.66%, Reliance 14.81%. Turnover as a multiple of market value gives the same order: 9.6, 4.7, 1.5 and 0.14 times. EPS growth rates were not confirmed. Next: the November Sangrix delivery, the Alaunos proxy and the October 23 Netcapital plan.






Please wait processing your request...